Glenmark Pharmaceuticals Ltd.
Pharma · NSE
52-week range
₹1,352 – ₹2,474
From 52w high
-4.3%
RSI (14)
61.1
vs SMA 50 / 200
↑ 50 · ↑ 200
Glenmark Pharmaceuticals trades at ₹2,366, up 68.7% over 12 months and above both its 50-day (₹2,208) and 200-day (₹2,039) moving averages, with a 52-week drawdown of only 4.4%. The trailing PE of 62.9 reflects a profit margin of 6.45% on 5-year revenue growth of 15.1%, while a debt-to-equity ratio of 12.78 stands as the most prominent structural overhang in the financials.
- ✓Price momentum: up 68.7% over 12 months and 20.8% over 3 months, trading above both SMA-50 and SMA-200 with RSI at 61 — momentum is intact without entering overbought territory.
- ✓5-year revenue and earnings growth both in the mid-teens (15.1% and 15.8% respectively), indicating sustained top-line and bottom-line expansion over the medium term.
- ✓Debt trend is classified as falling, suggesting active deleveraging is underway despite the absolute D/E level remaining elevated at 12.78.
- ✓Forward PE of 29.6 is substantially below the trailing PE of 62.9, implying the market is pricing in a significant improvement in earnings in the near term relative to current profitability.
- ✗Debt-to-equity of 12.78 is substantially above pharma sector norms; even with a falling debt trend, the absolute leverage level introduces meaningful solvency sensitivity to revenue disruptions.
- ✗ROE has not exceeded 15% in any tracked year and is currently unavailable, pointing to persistent challenges in generating adequate returns on shareholders equity; the persistence consistency score of 20/100 underscores this.
- ✗Free cash flow was positive in only 2 of tracked years, meaning the company has historically consumed cash more often than generated it — a concern when servicing a high debt load.
- ✗Quality score of 41 ranks 4th of 6 in the sector peer group, below MAXHEALTH (54) and SUNPHARMA (50), and the trailing PE of 62.9 is among the highest in the peer set despite a below-median quality profile.
- ·Several broker and media outlets published technical ideas with specific price targets for Glenmark in late April and early May 2026, including Motilal Oswal and Religare Broking — these represent third-party broker views, not VivaTrades analysis.
- ·A business development headline from Business Wire referenced a commercial transition related to home delivery, suggesting ongoing operational and product-reach activity in the near term.
- ·All 7 tracked news items over the recent window carried either positive (4) or neutral (3) sentiment, with zero negative items — a relatively clean near-term news backdrop, though the sample is small at 7 articles.
- ?Does the falling debt trend reflect genuine deleveraging from operating cash flows, or is it being driven by asset sales or refinancing that may introduce other obligations?
- ?How much of the 68.7% 1-year price gain is attributable to a re-rating of the multiple versus actual earnings improvement, and does the forward PE of 29.6 assume growth rates that have been consistently delivered historically?
- ?Given that FCF was positive in only 2 of tracked years, what is the sustainability of debt servicing at a D/E of 12.78 if revenue growth moderates from the 15.1% 5-year average?
- ?Does Glenmark's quality score of 41 — ranking 4th of 6 peers — reflect temporary factors such as a product mix shift or R&D investment cycle, or is it indicative of a structural competitive disadvantage versus peers like SUNPHARMA and MAXHEALTH?
PE
62.9
Forward PE
29.6
ROE
—
Profit margin
+6.5%
D/E
12.78
Dividend yield
+0.2%
Quality score
41/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
2/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.